Literature DB >> 32966782

SFPQ Depletion Is Synthetically Lethal with BRAFV600E in Colorectal Cancer Cells.

Kathleen Klotz-Noack1, Bertram Klinger2, Maria Rivera3, Natalie Bublitz1, Florian Uhlitz2, Pamela Riemer4, Mareen Lüthen1, Thomas Sell2, Katharina Kasack1, Bastian Gastl4, Sylvia S S Ispasanie4, Tincy Simon4, Nicole Janssen5, Matthias Schwab6, Johannes Zuber7, David Horst1, Nils Blüthgen8, Reinhold Schäfer9, Markus Morkel1, Christine Sers10.   

Abstract

Oncoproteins such as the BRAFV600E kinase endow cancer cells with malignant properties, but they also create unique vulnerabilities. Targeting of BRAFV600E-driven cytoplasmic signaling networks has proved ineffective, as patients regularly relapse with reactivation of the targeted pathways. We identify the nuclear protein SFPQ to be synthetically lethal with BRAFV600E in a loss-of-function shRNA screen. SFPQ depletion decreases proliferation and specifically induces S-phase arrest and apoptosis in BRAFV600E-driven colorectal and melanoma cells. Mechanistically, SFPQ loss in BRAF-mutant cancer cells triggers the Chk1-dependent replication checkpoint, results in decreased numbers and reduced activities of replication factories, and increases collision between replication and transcription. We find that BRAFV600E-mutant cancer cells and organoids are sensitive to combinations of Chk1 inhibitors and chemically induced replication stress, pointing toward future therapeutic approaches exploiting nuclear vulnerabilities induced by BRAFV600E.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chk1; DNA damage; MAPK signaling; R loops; cell death; organoids; replication stress; synthetic lethality; xenograft

Mesh:

Substances:

Year:  2020        PMID: 32966782     DOI: 10.1016/j.celrep.2020.108184

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  10 in total

1.  SFPQ promotes RAS-mutant cancer cell growth by modulating 5'-UTR mediated translational control of CK1α.

Authors:  Venetia Jing Tong Kok; Jia Ying Tang; Gracie Wee Ling Eng; Shin Yi Tan; Joseph Tin Foong Chin; Chun Hian Quek; Wei Xuan Lai; Teck Kwang Lim; Qingsong Lin; John Jia En Chua; Jit Kong Cheong
Journal:  NAR Cancer       Date:  2022-09-27

Review 2.  Nuclear Receptor Coregulators in Hormone-Dependent Cancers.

Authors:  Hedieh Jafari; Shahid Hussain; Moray J Campbell
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

3.  SFPQ rescues F508del-CFTR expression and function in cystic fibrosis bronchial epithelial cells.

Authors:  Parameet Kumar; Dharmendra Kumar Soni; Chaitali Sen; Mads B Larsen; Krystyna Mazan-Mamczarz; Yulan Piao; Supriyo De; Myriam Gorospe; Raymond A Frizzell; Roopa Biswas
Journal:  Sci Rep       Date:  2021-08-17       Impact factor: 4.996

4.  SFPQ Promotes Lung Cancer Malignancy via Regulation of CD44 v6 Expression.

Authors:  Libang Yang; Jianbo Yang; Blake Jacobson; Adam Gilbertsen; Karen Smith; LeeAnn Higgins; Candace Guerrero; Hong Xia; Craig A Henke; Jizhen Lin
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

5.  Transcriptome analysis of clock disrupted cancer cells reveals differential alternative splicing of cancer hallmarks genes.

Authors:  Deeksha Malhan; Alireza Basti; Angela Relógio
Journal:  NPJ Syst Biol Appl       Date:  2022-05-12

6.  Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition.

Authors:  Nezihi Murat Karabacak; Yu Zheng; Taronish D Dubash; Risa Burr; Douglas S Micalizzi; Ben S Wittner; Maoxuan Lin; Devon F Wiley; Valentine Comaills; Erin Emmons; Kira L Niederhoffer; Uyen Ho; Jacob Ukleja; Dante Che; Hannah Stowe; Linda T Nieman; Wilhelm Haas; Shannon L Stott; Michael S Lawrence; David T Ting; David T Miyamoto; Daniel A Haber; Mehmet Toner; Shyamala Maheswaran
Journal:  Cancer Res       Date:  2022-03-15       Impact factor: 13.312

7.  LncRNA-422 suppresses the proliferation and growth of colorectal cancer cells by targeting SFPQ.

Authors:  Yixuan Meng; Shuwei Li; Qiuyi Zhang; Shuai Ben; Qiuyuan Zhu; Mulong Du; Dongying Gu
Journal:  Clin Transl Med       Date:  2022-01

8.  A human ex vivo coculture model to investigate peritoneal metastasis and innovative treatment options.

Authors:  Dina Mönch; Jana Koch; Annika Maaß; Nicole Janssen; Thomas Mürdter; Philipp Renner; Petra Fallier-Becker; Wiebke Solaß; Matthias Schwab; Marc-H Dahlke; Hans J Schlitt; Tobias Leibold
Journal:  Pleura Peritoneum       Date:  2021-07-27

9.  Development of Metabolic Synthetic Lethality and Its Implications for Thyroid Cancer.

Authors:  Sang-Hyeon Ju; Seong Eun Lee; Yea Eun Kang; Minho Shong
Journal:  Endocrinol Metab (Seoul)       Date:  2022-02-28

Review 10.  Identifying Novel Actionable Targets in Colon Cancer.

Authors:  Maria Grazia Cerrito; Emanuela Grassilli
Journal:  Biomedicines       Date:  2021-05-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.